Eisbach Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $4.75M

  • Investors
  • 8

Eisbach General Information

Description

Developer of novel medicines designed to target chromatin regulatory mechanisms. The company focuses on molecular vulnerabilities arising in cancer genomes by leveraging epigenetic mechanisms to stop tumor growth and support new cancer therapies, enabling healthcare professionals to address unmet clinical needs.

Contact Information

Website
www.eisbach.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Am Klopferspitz 19
  • 82152 Planegg
  • Germany
+49 089
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Am Klopferspitz 19
  • 82152 Planegg
  • Germany
+49 089

Eisbach Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eisbach Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 26-Nov-2024 $4.75M Completed Clinical Trials - Phase 1
7. Later Stage VC 21-Mar-2024 Completed Clinical Trials - Phase 1
6. Grant 29-Oct-2021 Completed Clinical Trials - Phase 1
5. Grant 04-Jan-2021 Completed Clinical Trials - Phase 1
4. Seed Round 28-Oct-2020 Completed Clinical Trials - Phase 1
3. Grant 27-Jun-2019 Completed Startup
2. Accelerator/Incubator 01-Jan-2019 Completed Startup
1. Accelerator/Incubator 01-Jan-2019 Completed Startup
To view Eisbach’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eisbach Patents

Eisbach Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025242703-A1 Crystalline forms of an alc1 inhibitor useful in the treatment of cancer Pending 21-May-2024
EP-4801503-A1 Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan Pending 31-Oct-2023
WO-2025093706-A1 Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan Inactive 31-Oct-2023
AU-2024367467-A1 A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers Pending 25-Oct-2023
EP-4798196-A1 A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers Pending 25-Oct-2023 A61K31/519
To view Eisbach’s complete patent history, request access »

Eisbach Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eisbach Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cancer Prevention and Research Institute of Texas Government
Cancer Focus Fund Venture Capital Minority
Bavarian Ministry of Economic Affairs and Media, Energy and Technology Government
Bundesministerium für Bildung und Forschung Government
Angel (individual) Minority
You’re viewing 5 of 8 investors. Get the full list »

Eisbach FAQs

  • When was Eisbach founded?

    Eisbach was founded in 2019.

  • Where is Eisbach headquartered?

    Eisbach is headquartered in Planegg, Germany.

  • What is the size of Eisbach?

    Eisbach has 14 total employees.

  • What industry is Eisbach in?

    Eisbach’s primary industry is Drug Discovery.

  • Is Eisbach a private or public company?

    Eisbach is a Private company.

  • What is Eisbach’s current revenue?

    The current revenue for Eisbach is .

  • How much funding has Eisbach raised over time?

    Eisbach has raised $12.5M.

  • Who are Eisbach’s investors?

    Cancer Prevention and Research Institute of Texas, Cancer Focus Fund, Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Bundesministerium für Bildung und Forschung, and are 5 of 8 investors who have invested in Eisbach.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process